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In that respect, it is interesting to note in the letter from Uter
et al. (2001) that the percentage of colophony sensitive patients
reacting to oakmoss is increasing with regard to the severity of their
allergy. Thus the percentage of patients reacting to oakmoss is
14.7% in patients reacting to colophony with erythema only (``?''),
19.4% in those with a ``+'' reaction, 30% in those with a ``++''
reaction, and 53.3% in those with very strong (``+++'') reactions.
This later ®gure is very similar to the one we observed (53%) on
our selected patients.
We suggest that more care should be taken when stating that
12823 patients were patch tested between 1992 and 1999 to the
same oakmoss material as the one we have been using in our study.
Over a period of time patch test suppliers will use different batches
of oakmoss material either from the same supplier or from different
suppliers. The oak moss sample we have been using is identical to
the material used by Trolab (Reinbek, Germany) from 1999 to
now. Therefore a comparison of data can only be valid if conducted
in the period 1999±2000.
We are of course well aware that oakmoss and treemoss are skin
sensitizers, not only because of the presence of resin acids but also
because of the presence of other sensitizers, some of which are
known in the literature (Dahlquist et al., 1980). Among our 17
patients two reacted to the oakmoss from Chemotechnique
(MalmoÈ, Sweden), despite a low content of resin acid, which
probably indicates a true co-sensitization to oakmoss and
colophony.
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Staphylococcal Colonization in Atopic Dermatitis Treatment
with Topical Tacrolimus (Fk506)
To the Editor:
Tacrolimus (FK506) is a potent immunosuppressive macrolide.
Clinical trials have demonstrated that it is an effective topical
treatment for atopic dermatitis (AD) in adults as well as in children
(Ruzicka et al, 1997; Boguniewicz et al, 1998). Experience from
these trials suggests that an ephemeral burning sensation is the most
common drug-related side-effect; however, skin infections are a
potential complication of local treatment with topical immuno-
suppressive agents, and a recent open-label multicenter study,
involving 316 AD patients treated with 0.1% tacrolimus ointment
for 6±12 months, observed skin infections at the application site in
19.8% of patients (Reitamo et al, 2000). Heavy skin colonization
with Staphylococcus aureus is well established in patients with AD,
even in the absence of clinical signs of skin infection, and also on
normal skin (Hauser et al, 1985; Lever et al, 1988).
As tacrolimus has no antistaphylococcal activity in vitro (Kino et al,
1987), topical treatment with FK-506 might enhance S. aureus
colonization by a local immunosuppressive mechanism. Therefore,
we conducted a pilot study in order to determine the in¯uence of
treatment with 0.1% tacrolimus ointment on S. aureus colonization.
Tacrolimus ointment 0.1% was formulated according to Aoyama
et al (1995).
In 11 patients (mean age 23.2 [SD 13.8]) diagnosed with AD
according to the criteria of Hanni®n and Rajka (1980), we
identi®ed 40 lesional skin sites positive for S. aureus colonization.
All patients had stopped systemic or topical antibiotic treatments at
least 2 wk before onset of treatment with 0.1% tacrolimus
ointment; the use of emollients was allowed throughout the study
period. Staphylococcus aureus colonization density was measured as
the number of agglutination-positive colony forming units (CFU
per cm2) (Pastorex Staph-plus, Sano® Pasteur, Marnes La Coquette,
France), sampled with a mannitol salt agar contact plate (Ecobion,
Carouge, Switzerland). Assessment of S. aureus colonization density
at each site was done at baseline (day 0), and scheduled on days 3, 7,
14, and 21 after the onset of 0.1% tacrolimus ointment
monotherapy. In total, 151 samples were realized, which represents
75.5% of the scheduled number (n = 200). Of these, 139 samples
(92.1%) could be evaluated; 7.9% of the realized samples could not
be processed because of technical problems. We also studied 11 S.
aureus positive lesional skin sites in 11 patients (mean age 27.3 [SD
9.5]) that were treated with the vehicle alone. In order to correlate
S.aureus colonization density at each site with parameters of
treatment ef®cacy, we performed clinical grading based on the
lesional score of the SCORAD index (Consensus report ETFAD),
and assessed transepidermal water loss (TEWL), a parameter of skin
barrier function (EP2 evaporimeter, ServoMed AB, Kinna,
Sweden). Statistical comparison was made using the Wilcoxon
signed-rank test, a nonparametric test; rank correlation analysis was
made using the Spearman test.
During treatment with 0.1% tacrolimus ointment, TEWL and
lesional score showed a signi®cant decrease already after the third
day of therapy (p < 0.03 and p < 0.001, respectively), whereas
decrease of S. aureus colonization became signi®cant at treatment
day 7 (p < 0.003) (Fig 1). Statistical analysis according to the
Spearman test showed no correlation between the three parameters
(score, TEWL, and S. aureus colonization) studied at days 0, 3, 7,
14, and 21. In 31 samples, signi®cant but transient increases of
S. aureus CFU counts, as compared with preceding levels at the
same skin site, were observed at some point during the 21-d
treatment period (p < 0.05), without simultaneous changes of the
clinical score and TEWL.
Our results demonstrate that topical immunosuppressive therapy
of AD with 0.1% tacrolimus ointment during 3 wk is associated
with an overall decrease of S. aureus colonization on lesional skin.
Similar results have been reported with local steroid monotherapy,
which has also been shown to reduce S. aureus colonization on AD
skin (Nilsson et al, 1992). These ®ndings are consistent with the
concept of in¯ammatory skin condition in AD, being itself a
predisposing factor for colonization with S. aureus. This hypothesis
has some limitation insofar as the day-to-day variation of S. aureus
colonization in untreated skin of patients with AD is not known. As
tacrolimus does not have a direct antistaphylococcal activity (Kino
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et al, 1987), it is conceivable that the decrease of S. aureus
colonization observed in this study is a consequence of the
improvement of the skin surface due to the anti-in¯ammatory
effect of the drug, and possibly also due to the emollient effect of
the vehicle. This is supported by our observation that the onset of
signi®cance for the decrease of S. aureus colonization at treatment
day 7 lagged behind the evolution of the clinical score and the skin
barrier function, that had already signi®cantly improved by day 3.
Alternatively, S. aureus CFU density might be a more sensitive
parameter of AD severity than the clinical score and TEWL, and
thus lag behind the evolution of the latter during immunosuppres-
sive local treatment. Our observation that a substantial number of
samples showed transient increases in S. aureus colonies during
continued treatment, despite a rapid decrease of baseline S. aureus
counts at onset of immunosuppressive treatment, suggests however
that S. aureus colonization is an independent disease parameter in
AD, whose dynamics under topical immunosuppressive treatment
need further study.
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Figure 1. Evolution of clinical parameters
during treatment of atopic dermatitis lesional
skin sites with tacrolimus ointment. (A)
Staphylococcus aureus colony forming units (CFU
per cm2) count; (B) lesional SCORAD score; (C)
transepidermal water loss (TEWL); *p < 0.05
(Wilcoxon signed-rank test).
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